TY - JOUR
T1 - Gene supplementation therapy restores motor deficits in Gnao1[C215Y] mice and proves broad efficacy in C. elegans model
AU - Cocozza, Germana
AU - D’Andrea, Tiziano
AU - Di Rocco, Martina
AU - Busdraghi, Ludovica Maria
AU - Chilà, Gilda
AU - Lin, Xingzi
AU - Lanza, Enrico
AU - Collaud, Fanny
AU - Follo, Francesca C.
AU - Buccheri, Clelia
AU - Folli, Viola
AU - Ronzitti, Giuseppe
AU - Scavizzi, Ferdinando
AU - Raspa, Marcello
AU - Leuzzi, Vincenzo
AU - Katanaev, Vladimir L.
AU - Galosi, Serena
AU - Fucile, Sergio
AU - Martinelli, Simone
AU - D’Alessandro, Giuseppina
AU - Limatola, Cristina
N1 - Publisher Copyright:
© The Author(s) 2026.
PY - 2026/12
Y1 - 2026/12
N2 - The heterotrimeric G proteins are ubiquitous membrane-bound complexes specialized in the transduction of receptor-mediated extracellular signals into intracellular responses. Mutations in the G protein subunit alpha O1 (Gαo), encoded by GNAO1, have been associated with neurodevelopmental disorders characterized by prominent movement disorder with or without epilepsy. The Gnao1[C215Y]/+ mouse model recapitulates key features of the human disease, with a relatively mild phenotype, normal viability and late onset movement abnormalities, detectable in specific motor tasks. Here we report functional alterations in cortical layer V pyramidal neurons from Gnao1[C215Y]/+ mice, with reduction of the inward currents (Ih) and impairment of the GABAB-mediated outward current. We propose an adeno-associated virus (AAV)-based gene therapy aimed at overexpressing the wild-type form of Gαo by intracerebroventricular injection in newborn heterozygous Gnao1[C215Y]/ + mice. Our results demonstrate that overexpression of the wild-type protein mitigates behavioral abnormalities and restores functional neuronal deficits in young adult mice, thereby supporting the development of AAV-mediated gene augmentation strategies to counteract the effects of GNAO1 variants in patients. The potential of gene supplementation therapy is further supported by data from genetically modified C. elegans strains carrying not only the relatively mild C215Y variant but also a panel of goa-1/GNAO1 mutations associated with more severe phenotypes, suggesting a broader potential of this therapeutic strategy.
AB - The heterotrimeric G proteins are ubiquitous membrane-bound complexes specialized in the transduction of receptor-mediated extracellular signals into intracellular responses. Mutations in the G protein subunit alpha O1 (Gαo), encoded by GNAO1, have been associated with neurodevelopmental disorders characterized by prominent movement disorder with or without epilepsy. The Gnao1[C215Y]/+ mouse model recapitulates key features of the human disease, with a relatively mild phenotype, normal viability and late onset movement abnormalities, detectable in specific motor tasks. Here we report functional alterations in cortical layer V pyramidal neurons from Gnao1[C215Y]/+ mice, with reduction of the inward currents (Ih) and impairment of the GABAB-mediated outward current. We propose an adeno-associated virus (AAV)-based gene therapy aimed at overexpressing the wild-type form of Gαo by intracerebroventricular injection in newborn heterozygous Gnao1[C215Y]/ + mice. Our results demonstrate that overexpression of the wild-type protein mitigates behavioral abnormalities and restores functional neuronal deficits in young adult mice, thereby supporting the development of AAV-mediated gene augmentation strategies to counteract the effects of GNAO1 variants in patients. The potential of gene supplementation therapy is further supported by data from genetically modified C. elegans strains carrying not only the relatively mild C215Y variant but also a panel of goa-1/GNAO1 mutations associated with more severe phenotypes, suggesting a broader potential of this therapeutic strategy.
KW - Behavioral tests
KW - C. elegans
KW - Electrophysiological recordings
KW - GNAO1
KW - Gene therapy
KW - Gαo
KW - Mouse model
UR - https://www.scopus.com/pages/publications/105053890764
U2 - 10.1186/s40478-026-02389-6
DO - 10.1186/s40478-026-02389-6
M3 - Article
C2 - 42482114
AN - SCOPUS:105053890764
SN - 2051-5960
VL - 14
JO - Acta neuropathologica communications
JF - Acta neuropathologica communications
IS - 1
M1 - 217
ER -